BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 6, 2024
See today's BioWorld
Home
» Acacia's Barhemsys hit with second CRL; CMO troubles persist
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Acacia's Barhemsys hit with second CRL; CMO troubles persist
May 6, 2019
By
Nuala Moran
No Comments
LONDON – Acacia Pharma Group plc has been hit with a second complete response letter (CRL) for its postoperative nausea and vomiting (PONV) product, Barhemsys, with the FDA still unhappy following re-inspection of the contract manufacturer's site.
BioWorld